相关实验视频

Updated: Feb 18, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

GLP-1受体激活剂启动和结肠直肠癌和结肠的风险

Anwar Alshaakh Moh'd Mari¹, Faris Alamin¹, Minh Anh Le¹

¹University of Central Florida HCA Florida Healthcare, Greater Orlando, Florida, USA; Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.

The American journal of the medical sciences

|February 16, 2026

概括

类似葡萄糖-1受体激动剂 (GLP-1RA) 没有对结直肠癌 (CRC) 风险产生影响,但与糖尿病患者的结肠的更高发病率有关.

科学领域:

内分泌学在内分泌学.
胃肠病学胃肠病学
在瘤学瘤学.

背景情况:

关于葡萄糖类-1受体激动剂 (GLP-1RA) 与结直肠癌 (CRC) 风险之间的关联,存在相互矛盾的证据.
一些研究表明GLP-1RA可能会降低CRC风险,而另一些研究则表明它有可能促进瘤发生.

研究的目的:

调查GLP-1RA使用与发生CRC的风险之间的关联.
检查GLP-1RA使用与结肠的发病率之间的关联.

主要方法:

从2006年到2021年进行了一项回顾性倾向评分 (PS) 匹配的队列研究.
包括开始使用GLP-1RA或二乙酶-4抑制剂 (DPP-4i) 的成年人,使用61个变量进行PS匹配.
分析了两个队列:一个主要队列和一个不含息肉的队列,不包括基线结肠息肉.

主要成果:

在GLP-1RA用户 (0.2%) 和DPP-4i用户 (0.3%) 之间没有观察到CRC发病率的显著差异 (OR:0.99;95%CI:0.84-1.17)).
与DPP-4i用户 (5.3%) 相比,GLP-1RA用户的结肠多发生率较高 (5.9%). (OR: 1.12;95%CI: 1.08-1.17) 与DPP-4i用户相比,GLP-1RA用户的结肠多发生率较高 (5.9%).
这些发现在主要和无聚合体队伍中都是一致的.

结论:

糖尿病患者的GLP-1RA使用与CRC风险降低或增加无关.
与DPP-4i使用相比,GLP-1RA使用与发生结肠的风险更高.

关键词:

结肠的多重体是什么意思作为GLP-1受体的激动剂.结肠直肠癌是什么意思双基酸酶-4抑制剂的使用.

更多相关视频

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...